These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 7353370

  • 1. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease.
    Kanis JA, Russell RG, Cundy T, Earnshaw M, Woods CG, Smith R, Heynen G.
    Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370
    [Abstract] [Full Text] [Related]

  • 2. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3.
    Voigts AL, Felsenfeld AJ, Llach F.
    Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827
    [Abstract] [Full Text] [Related]

  • 3. Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses.
    Kanis JA, Cundy T, Earnshaw M, Henderson RG, Heynen G, Naik R, Russell RG, Smith R, Woods CG.
    Q J Med; 1979 Apr; 48(190):289-322. PubMed ID: 504552
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
    Christiansen C, Røodbro P, Christensen MS, Naestoft J, Hartnack B, Transbøol I.
    Contrib Nephrol; 1980 Apr; 18():139-46. PubMed ID: 6243527
    [Abstract] [Full Text] [Related]

  • 6. Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure.
    Sherrard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N.
    Contrib Nephrol; 1980 Apr; 18():92-7. PubMed ID: 7353382
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.
    Cameron EC, Prior JC, Ballon HS.
    Contrib Nephrol; 1980 Apr; 18():162-71. PubMed ID: 6986229
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG, Goldstein DA, Malluche HH.
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N, Catto GR, Edward N, Fraser RA, O'Riordan JL, Papapoulos SE, Adami S.
    Proc Eur Dial Transplant Assoc; 1980 Oct; 17():543-7. PubMed ID: 6972529
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.